Sunovion Pharmaceuticals Inc. chose an Aptar Pharma Landmark dose indicator for Zetonna, a dry nasal aerosol for the treatment of allergic rhinitis. Zetonna (ciclesonide) is a corticosteroid indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. Zetonna became available July 30 in the United States.
According to Aptar Pharma, each canister of Zetonna nasal aerosol contains enough medicine for 60 metered
actuations, equivalent to one month of treatment. A customized dose indicator keeps track of actuations. Landmark won a FEA (European Aerosol Federation) international aerosol award in 2007.
Zetonna is formulated with hydrofl uoroalkane (HFA) propellant in a pressurized metered-dose inhaler (pMDI). The Landmark device counts downward and provides the patient with a visual color and numerical reference when it is time to refi ll the prescription before the container becomes empty, reports Aptar. The dose-counting mechanism operates independently from the patient’s actuation force. A plastic cap attached to the device itself protect the nose tip from dust.
FDA advises drug manufacturers to use a dose-counting device into new pMDI drug products, Aptar Pharma reports.
“The collaboration between Aptar Pharma and Sunovion is a source of great satisfaction, and we are
particularly proud to have developed this customized device for ZETONNA,” said Pierre Carlotti, Vice
President Marketing and Communication for Aptar Pharma Prescription Division, in a press release.
“The launch of ZETONNA Nasal Aerosol in the United States is an important milestone for Sunovion, and
provides another treatment option for the millions of patients suffering from allergic rhinitis,” added Ted Raad, Vice President Sales & Marketing for Sunovion, in the press release. “Aptar Pharma’s Landmark® indicator has
played an key role in the development of ZETONNA.”